Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma

References

• Sehn L H, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23: 5027–5033
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379–391
   PubMed Web of Science ®Google Scholar
• Polo J M, Juszczynski P, Monti S, Cerchietti L, Ye K, Greally J M, et al. Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proc Natl Acad Sci USA 2007; 104: 3207–3212
   PubMed Web of Science ®Google Scholar
• Berliner N, Linker C, Schiffer C. Optimal use of prognostic factors in non-Hodgkin lymphoma. Hematology, Education Program Book. The American Society of Hematology 48th Annual Meeting, Orlando, December 2006. The American Society of Hematology Publisher, Washington, DC 2006; 295–302
   Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Project TIN-HsLPF. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Sehn L H, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857–1861
   PubMed Web of Science ®Google Scholar
• Porrata L F, Gertz M A, Inwards D J, Litzow M R, Lacy M Q, Tefferi A, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001; 98: 579–585
   PubMed Web of Science ®Google Scholar
• Siddiqui M, Ristow K, Markovic S N, Witzig T E, Habermann T M, Colgan J P, et al. Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol 2006; 134: 596–601
   PubMed Web of Science ®Google Scholar
• Behl D, Ristow K, Markovic S N, Witzig T E, Habermann T M, Colgan J P, et al. Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas. Br J Haematol 2007; 137: 409–415
   PubMed Web of Science ®Google Scholar
• Kim D H, Baek J H, Chae Y S, Kim Y K, Kim H J, Park Y H, et al. Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia 2007; 21: 2227–2230
   PubMed Web of Science ®Google Scholar
• Plonquet A, Haioun C, Jais J P, Debard A L, Salles G, Bene M C, et al. Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2–3 diffuse large B-cell lymphoma. Ann Oncol 2007; 18: 1209–1215
   PubMed Web of Science ®Google Scholar
• Hill Q A, Owen R G. CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev 2006; 20: 319–332
   PubMed Web of Science ®Google Scholar
• Rodriguez V, Cabanillas F, Burgess M A, McKelvey E M, Valdivieso M, Bodey G P, et al. Combination chemotherapy (“CHOP-Bleo”) in advanced (non-Hodgkin) malignant lymphoma. Blood 1977; 49: 325–333
   PubMed Web of Science ®Google Scholar
• Klimo P, Connors J M. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med 1985; 102: 596–602
   PubMed Web of Science ®Google Scholar
• Halaas J L, Moskowitz C H, Horwitz S, Portlock C, Noy A, Straus D, et al. R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy. Leuk Lymphoma 2005; 46: 541–547
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas. J Clin Oncol 1999; 17: 1244–1253
   PubMed Web of Science ®Google Scholar
• Cheson B D, Pfistner B, Juweid M E, Gascoyne R D, Specht L, Horning S J, et al. The International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579–586
   PubMed Web of Science ®Google Scholar
• Velasquez W S, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71: 117–122
   PubMed Web of Science ®Google Scholar
• Philip T, Biron P, Maraninchi D, Gastaut J A, Hervé P, Flesh Y, et al. Role of massive chemotherapy and autologous bone-marrow transplantation in non-Hodgkin's malignant lymphoma. Lancet 1984; 1: 391
   PubMed Web of Science ®Google Scholar
• Franklin J, Paulus U, Lieberz D, Breuer K, Tesch H, Diehl V. Is the international prognostic score for advanced stage Hodgkin's disease applicable to early stage patients? German Hodgkin Lymphoma Study Group. Ann Oncol 2000; 11: 617–623
   PubMed Web of Science ®Google Scholar
• Porrata L F, Ristow K, Witzig T E, Tuinistra N, Habermann T M, Inwards D J, et al. Absolute lymphocyte count predicts therapeutic efficacy and survival at the time of radioimmunotherapy in patients with relapsed follicular lymphomas. Leukemia 2007; 21: 2554–2556
   PubMed Web of Science ®Google Scholar
• Cox M C, Nofroni I, La Verde G, Ferrari A, Amodeo R, Tatarelli C, et al. Absolute lymphocyte count is a prognostic factor in diffuse-large-B-cell lymphoma. Br J Haematol 2008; 141: 265–267
   PubMed Web of Science ®Google Scholar
• Behl D, Porrata L F, Markovic S N, Letendre L, Pruthi R K, Hook C C, et al. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia 2006; 20: 29–34
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Spedini P, Casari S, Re A, Tucci A, Borlenghi E, et al. Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma 2006; 47: 1013–1017
   PubMed Web of Science ®Google Scholar
• Tzankov A, Meier C, Hirschmann P, Went P, Pileri S A, Dirnhofer S. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 2008; 93: 193–200
   PubMed Web of Science ®Google Scholar